gs nucleosid analogu antivir drug develop gilead scienc main plasma metabolit antivir prodrug remdesivir halflif around hour human patient remdesivir gs find effect vitro felin coronavirus strain respons felin infecti periton fip lethal system diseas affect domest cat remdesivir never test cat though vet offer gs find effect treatment fip wide use despit offici fda approv due gilead refus licens drug veterinari use sinc fip usual fatal approv treatment avail gs report sell black market use pet owner treat affect cat although gilead scienc refus licens drug veterinari use efficaci purpos conclus demonstr multipl trial includ field trial even complic form fip multisystem neurolog involv gs either similar potent remdesivir sarscov cell cultur research argu gs would well remdesivir treatment covid specif advantag cite includ eas synthesi low kidney hepatotox well potenti oral deliveri preclud remdesivir poor hepat stabil first pass metabol public health advocaci group public citizen open letter urg dhhs gilead investig gs treatment covid suggest gilead financi motiv relat long intellectu properti lifespan remdesivir direct efficaci sarscov demonstr mous model covid deuterium modifi version gs produc show preclin efficaci cell cultur mous model team includ member wuhan institut virolog gs sell research chemic high puriti nmr hplc number supplier includ medkoo selleckchem medchemexpress sale research purpos constitut patent infring affirm suprem court decisioncit need howev despit high puriti fda regul chemic allow clinic trial sinc manufactur perform fda cgmp certifi condit chemic like chemic may howev administ patient individu clinician discret practic part formal trial howev harm result use well legal protect malpractic claim use approv ethic pharmaceut drugscit need gs direct administ healthi human high plasma concentr um reach time concentr requir activ sarscov cultur g nucleosid phosphoryl nucleosid kinas probabl adenosin kinas adk enzym phosphoryl structur similar ribavirin phosphoryl nucleosidediphosph kinas ndk activ nucleotid triphosph form triphosph gs gs also bioactiv antivir agent generat remdesivir generat differ biochem mechan later gs cyanosubstitut adenosin analogu remdesivir predomin metabolit circul serum due rapid hydrolysi half life less hour follow dephosphoryl respons letter public citizen nation institut health drug discovey arm nation center advanc translat scienc ncat start systemat investig new drug enabl experi includ pharmacokinet multipl preclin speci also octob human result yet publishedcit need oral bioavail find excel dog good mous modest cynomolgus nonhuman primat predict human oral bioavail preclin datum art scienc reli model datum multipl speci take refer point clinic preclin datum nucleosid analogu human oral bioavail gs expect fall somewher see dog high point see nonhuman primat sinc g bite less half molecular weight remdesivir deliv much activ metabolit blood dose remdesivir exampl mg even human oral bioavail compar exampl ribavirin recent data releas ncat show gs toler mgkg dog maximum plasma concentr cmax near fold high concentr requir activ virus cell cultur elimin halflif gs around hour cynomolgus much short hour report human long half life suggest onceaday dose drug approv human oral use intracellular triplephosphoryl gs yield activ cyanosubstitut adenosin triphosph analogu direct disrupt viral rna replic compet endogen ntps incorpor nascent viral rna transcript trigger delay chain termin rnadepend rna polymeras vitro experi crandel ree felin kidney crfk cell find gs nontox concentr time dose effect inhibit fipv replic cultur crfk cell infect macrophag clinic trial cat indic drug welltoler primari side effect dermal irrit acid inject mix research suggest util treatment covid point advantag remdesivir includ lack ontarget liver toxic long halflif exposur auc much cheap simpl synthesi